专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005120479A1 USE OF SELENIUM OR A SELENIUM SALT AND A RETINOID ACID OR A RETINOID IN THE TREATMENT OF VIRAL HEPATITIS C 审中-公开
标题翻译：在治疗病毒性肝炎的过程中使用硒或硒酸盐和杀真菌酸或抗真菌剂
公开(公告)号：WO2005120479A1
公开(公告)日：2005-12-22
申请号：PCT/EP2005/006226
申请日：2005-06-09
申请人： GPC BIOTECH AG , HERGET, Thomas , KLEBL, Bert
发明人： HERGET, Thomas , KLEBL, Bert
IPC分类号： A61K31/095
CPC分类号： A61K33/04 , A61K31/07 , A61K31/095 , A61K31/203 , A61K31/7056 , A61K38/21 , A61K2300/00
摘要： The present invention relates to combination therapies comprising at least one retinoid or retinoid agonist together with selenium or a selenium salt particularly useful in conjunction with conventional antiviral therapeutics which are synergistically effective against Hepatitis C virus (HCV) infections. In particular, the present invention relates to the synergism between compounds capable of activating or upregulating the gastrointestinal form of glutathione peroxidase for prophylaxis and/or treatment of HCV infections, administered in combination therapies with interferons. The combinations disclosed have proven surprisingly effective even in patients unresponsive to interferon/ribavirin therapies.
摘要翻译：本发明涉及包含至少一种类视黄醇或类视色素激动剂与硒或硒盐的组合疗法，其特别适用于与丙型肝炎病毒（HCV）感染协同有效的常规抗病毒治疗剂。特别地，本发明涉及能够激活或上调胃肠道形式的谷胱甘肽过氧化物酶用于预防和/或治疗HCV感染的化合物之间的协同作用，其与干扰素联合治疗。即使在对干扰素/利巴韦林治疗无反应的患者中，所公开的组合也已经被证明是惊人的。

2. 发明申请

WO2004050101A2 FORMULATIONS USEFUL AGAINST HEPATITIS C VIRUS INFECTIONS 审中-公开
标题翻译：用于治疗丙型肝炎病毒感染的制剂
公开(公告)号：WO2004050101A2
公开(公告)日：2004-06-17
申请号：PCT/EP2003/013514
申请日：2003-12-01
申请人： AXXIMA PHARMACEUTICALS AG , HERGET, Thomas , KLEBL, Bert
发明人： HERGET, Thomas , KLEBL, Bert
IPC分类号： A61K33/04
CPC分类号： A61K38/212 , A61K9/0014 , A61K9/2866 , A61K31/00 , A61K31/203 , A61K31/593 , A61K33/04 , A61K38/215 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： The present invention relates generally to chemical compounds and substances which are effective against Hepatitis C virus (HCV) infections. Moreover, the present invention relates to compositions comprising said compounds and/or substances, to methods for preventing HCV infections as well use of the compounds and/or substances for the preparation of compositions useful for the prophylaxis and/or treatment of HCV infections. Useful compounds and substances according to the invention are selenium, selenium salts, Vitamin D 3 and retinoids, like all trans retinoic acid and salts thereof, C 1 - C alkyl amide of all trans retinoic acid and salts thereof, C 1 - C 10 alkyl esters of all trans retinoic acid and salts thereof, 9-cis retinoic acid and salts thereof, C 1 - C 10 alkyl amide of 9-cis retinoic acid and salts thereof, C 1 - C 10 alkyl esters of 9-cis retinoic acid and salts thereof, (E)-4-[2 (5,6,7,8-tetrahydro-5,5,8,8-tetra methyl-2-naphthalenyl-1-propenyl) benzoic acid (TTNPB), (4-[5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphtalenyl) carboxamido] benzoic acid (AM-580), N-(4-hydroxyphenyl) retinamide (4-HPR), and 6-[3-(1- adamantyl) -4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN).
摘要翻译：本发明一般涉及对抗丙型肝炎病毒（HCV）感染有效的化合物和物质。此外，本发明涉及包含所述化合物和/或物质的组合物，预防HCV感染的方法以及使用该化合物和/或物质制备用于预防和/或治疗HCV感染的组合物。根据本发明的有用化合物和物质是硒，硒盐，维生素D 3和类视黄醇，如所有的反式视黄酸及其盐，C 1 -C 1烷基酰胺全反式视黄酸及其盐，全反式视黄酸及其盐的C 1 -C 10烷基酯，9-顺式视黄酸及其盐，C

3. 发明公开

EP1673346A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS 审中-公开
标题翻译：用于治疗疱疹病毒感染喹唑啉衍生物
公开(公告)号：EP1673346A1
公开(公告)日：2006-06-28
申请号：EP04790130.1
申请日：2004-10-05
申请人： GPC Biotech AG
发明人： HERGET, Thomas
IPC分类号： C07D215/44 , A61K31/517
CPC分类号： C07D215/44
摘要： The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.

4. 发明公开

EP1694670A1 PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES 审中-公开
标题翻译：吡嗪对活性化合物传染病
公开(公告)号：EP1694670A1
公开(公告)日：2006-08-30
申请号：EP04803982.0
申请日：2004-12-16
申请人： GPC Biotech AG
发明人： EIKHOFF, Jan, Eike , ASHTON, Mark Richard , COURTNEY, Stephen Martin , YARNOLD, Christopher John , VARRONE, Maurizio , LOKE, Pui Leng , HERGET, Thomas , SCHWAB, Wilfried , HAFENBRADL, Doris
IPC分类号： C07D403/12 , C07D409/14 , C07D401/04 , C07D241/20 , A61K31/4965 , A61K31/497
CPC分类号： C07D401/04 , C07D241/20 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/12 , C07D409/14
摘要： The present invention relates to pyrazine derivatives according to the general formula (I) and pharmaceutically acceptable salts thereof and their use as pharmaceutical compounds as well as the use of these compounds for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke and especially for the treatment of herpesviral induced infections, including opportunistic infections as well as infections and diseases caused by human cytomegalovirus (HCMV).

5. 发明公开

EP1678147A1 PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES 有权转让
标题翻译：药学有效4,6-二取代氨基嘧啶衍生物作为蛋白激酶的调节剂
公开(公告)号：EP1678147A1
公开(公告)日：2006-07-12
申请号：EP04786953.2
申请日：2004-09-15
申请人： GPC Biotech AG
发明人： CHOIDAS, Axel , BACKES, Alexander , COTTEN, Matt , ENGKVIST, Ola , FELBER, Beatrice , FREISLEBEN, Achim , GODL, Klaus , GREFF, Zoltán , HABENBERGER, Peter , HAFENBRADL, Doris , HARTUNG, Christian , HERGET, Thomas , HOPPE, Edmund , KLEBL, Bert , MISSIO, Andrea , MÜLLER, Gerhard , SCHWAB, Wilfried , ZECH, Birgit , BRAVO, Jose , HARRIS, John , LE, Joelle , MACRITCHIE, Jackie , SAVIC, Vladimir , SHERBORNE, Brad , SIMPSON, Don
IPC分类号： C07D239/42 , C07D401/12 , C07D239/48 , C07D403/12 , C07D401/04 , C07D409/12 , C07D417/12 , C07D405/12 , C07D409/14 , C07D413/12 , C07D409/04 , A61K31/505
CPC分类号： C04B35/632 , C07D239/42 , C07D239/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要： The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furhtermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

6. 发明公开

EP1567172A2 FORMULATIONS USEFUL AGAINST HEPATITIS C VIRUS INFECTIONS 审中-公开
标题翻译： PREPARATIONS为丙型肝炎感染的治疗
公开(公告)号：EP1567172A2
公开(公告)日：2005-08-31
申请号：EP03785699.4
申请日：2003-12-01
申请人： GPC Biotech AG
发明人： HERGET, Thomas , KLEBL, Bert
IPC分类号： A61K33/04 , A61P31/14 , A61K31/00
CPC分类号： A61K38/212 , A61K9/0014 , A61K9/2866 , A61K31/00 , A61K31/203 , A61K31/593 , A61K33/04 , A61K38/215 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： The present invention relates generally to chemical compounds and substances which are effective against Hepatitis C virus (HCV) infections. Moreover, the present invention relates to compositions comprising said compounds and/or substances, to methods for preventing HCV infections as well use of the compounds and/or substances for the preparation of compositions useful for the prophylaxis and/or treatment of HCV infections. Useful compounds and substances according to the invention are selenium, selenium salts, Vitamin D3 and retinoids, like all trans retinoic acid and salts thereof, C1 - C alkyl amide of all trans retinoic acid and salts thereof, C1 - C10 alkyl esters of all trans retinoic acid and salts thereof, 9-cis retinoic acid and salts thereof, C1 - C10 alkyl amide of 9-cis retinoic acid and salts thereof, C1 - C10 alkyl esters of 9-cis retinoic acid and salts thereof, (E)-4-[2 (5,6,7,8-tetrahydro-5,5,8,8-tetra methyl-2-naphthalenyl-1-propenyl) benzoic acid (TTNPB), (4-[5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphtalenyl) carboxamido] benzoic acid (AM-580), N-(4-hydroxyphenyl) retinamide (4-HPR), and 6-[3-(1- adamantyl) -4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN).

7. 发明申请

WO2002084294A2 HUMAN CELLULAR PROTEIN GASTROINTESTINAL GLUTATHIONE PEROXIDASE AS TARGET FOR MEDICAL INTERVENTION AGAINST HEPATITIS C VIRUS INFECTIONS 审中-公开
标题翻译：人类细胞蛋白GASTROINTESTINAL GLUTATHIONE过氧化物作为针对乙型肝炎病毒感染的医疗干预措施
公开(公告)号：WO2002084294A2
公开(公告)日：2002-10-24
申请号：PCT/EP2002/004167
申请日：2002-04-15
申请人： AXXIMA PHARMACEUTICALS AG , HERGET, Thomas , COTTEN, Matthew , OBERT, Sabine
发明人： HERGET, Thomas , COTTEN, Matthew , OBERT, Sabine
IPC分类号： G01N33/576
CPC分类号： C12N9/0065 , A61K31/00 , A61K38/00 , A61K48/00 , A61K2039/505 , C12N2501/24 , C12Q1/28 , C12Y111/01009 , G01N33/573 , G01N33/5767 , G01N2333/18 , G01N2333/908 , G01N2500/04
摘要： The present invention relates to the human cellular protein glutathione peroxidase-gastrointestinal as potential targets for medical intervention against Hepatitis C virus (HCV) infections. Furthermore, the present invention relates to a method for the detection of compounds useful for prophylaxis and/or treatment of Hepatitis C virus infections and a method for detecting Hepatitic C virus infections in an individual or in cells. Also mono- or polyclonal antibodies are disclosed effective for the treatment of HCV infections together with methods for treating Hepatitis C virus infections or for the regulation of Hepatitis C virus production wherein said antibodies may be used.
摘要翻译：本发明涉及人类细胞蛋白谷胱甘肽过氧化物酶 - 胃肠道作为针对丙型肝炎病毒（HCV）感染的医疗干预的潜在靶标。此外，本发明涉及用于检测可用于预防和/或治疗丙型肝炎病毒感染的化合物的方法和用于检测个体或细胞中的肝炎C病毒感染的方法。还公开了对治疗HCV感染有效的单克隆抗体或多克隆抗体以及用于治疗丙型肝炎病毒感染的方法或用于调控可以使用所述抗体的丙型肝炎病毒生产。

8. 发明申请

WO2004016271A1 PYRIMIDONES AS ANTIVIRAL AGENTS 审中-公开
标题翻译：吡咯烷酮作为抗病毒剂
公开(公告)号：WO2004016271A1
公开(公告)日：2004-02-26
申请号：PCT/EP2003/009039
申请日：2003-08-14
申请人： AXXIMA PHARMACEUTICALS AG , 4SC AG , MISSIO, Andrea , HERGET, Thomas , ASCHENBRENNER, Andrea , KRAMER, Bernd , LEBAN, Johann , WOLF, Kristina
发明人： MISSIO, Andrea , HERGET, Thomas , ASCHENBRENNER, Andrea , KRAMER, Bernd , LEBAN, Johann , WOLF, Kristina
IPC分类号： A61K31/513
CPC分类号： C07D239/36 , C07D405/06
摘要： The present invention relates to vinylpyrimidine-2-one derivatives of general formula (I). Furthermore the present invention relates to vinylpyrimidine-2-one derivatives and of general formula (Ia), wherein R 1 to R 6 in formula (I) and in formula (Ia) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties.
摘要翻译：本发明涉及通式（I）的乙烯基嘧啶-2-酮衍生物。此外，本发明涉及乙烯基嘧啶-2-酮衍生物和通式（Ia），其中式（I）和式（Ia）中的R 1至R 6彼此独立地表示各种不同的取代基包括烷基，芳基，芳烷基，烷基芳基，杂芳基和单官能部分。

9. 发明申请

WO2013045033A1 METHOD OF DETERMINING THE STATUS OF CELLS 审中-公开
标题翻译：确定细胞状态的方法
公开(公告)号：WO2013045033A1
公开(公告)日：2013-04-04
申请号：PCT/EP2012/003818
申请日：2012-09-12
申请人： MERCK PATENT GMBH , BECHER, Burkhard , HENZLER, Tanja , HERGET, Thomas , WUENSCHE, Verena , ZENKE, Frank , SCHACHE, Janet
发明人： BECHER, Burkhard , HENZLER, Tanja , HERGET, Thomas , WUENSCHE, Verena , ZENKE, Frank , SCHACHE, Janet
IPC分类号： G01N33/50
CPC分类号： G01N33/5008 , G01N33/5014
摘要： The present invention is directed to a method and assay with which certain cellular parameters can be determined. This method and assay provides an effective means for assessing drug candidate liabilities (toxicities and side effects) to better predict safety early in the drug development process.
摘要翻译：本发明涉及可以确定某些细胞参数的方法和测定。该方法和测定法为评估药物候选药物负荷（毒性和副作用）提供了有效的手段，以更好地预测药物开发过程的早期安全性。

10. 发明申请

WO2005058876A1 PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES 审中-公开
标题翻译：吡哆醛衍生物作为有效的化合物对抗感染性疾病
公开(公告)号：WO2005058876A1
公开(公告)日：2005-06-30
申请号：PCT/EP2004/014371
申请日：2004-12-16
申请人： AXXIMA PHARMACEUTICALS AG , EIKHOFF, Jan, Eike , ASHTON, Mark, Richard , COURTNEY, Stephen, Martin , YARNOLD, Christopher, John , VARRONE, Maurizio , LOKE, Pui, Leng , HERGET, Thomas , SCHWAB, Wilfried , HAFENBRADL, Doris
发明人： EIKHOFF, Jan, Eike , ASHTON, Mark, Richard , COURTNEY, Stephen, Martin , YARNOLD, Christopher, John , VARRONE, Maurizio , LOKE, Pui, Leng , HERGET, Thomas , SCHWAB, Wilfried , HAFENBRADL, Doris
IPC分类号： C07D403/12
CPC分类号： C07D401/04 , C07D241/20 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/12 , C07D409/14
摘要： The present invention relates to pyrazine derivatives according to the general formula (I) and pharmaceutically acceptable salts thereof and their use as pharmaceutical compounds as well as the use of these compounds for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases, stroke and especially for the treatment of herpesviral induced infections, including opportunistic infections as well as infections and diseases caused by human cytomegalovirus (HCMV).
摘要翻译：本发明涉及根据通式（I）的吡嗪衍生物及其药学上可接受的盐及其作为药物化合物的用途，以及这些化合物在制备用于预防和/或治疗感染性疾病的药物组合物中的用途疾病，包括机会性疾病，朊病毒疾病，免疫疾病，自身免疫性疾病，双相和临床疾病，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经变性疾病，中风，特别是治疗疱疹病毒诱导的感染，包括机会性感染以及由巨细胞病毒（HCMV）引起的感染和疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式